Last updated: February 24, 2026
What is NDC 70954-0168?
NDC 70954-0168 refers to a specific formulation of a pharmaceutical drug registered in the National Drug Code system. Based on available data, this code corresponds to Bupivacaine HCl (0.75%) with Epinephrine (1:200,000), a local anesthetic used in surgical and dental procedures for regional anesthesia.
Market Overview
Indications and Use
Bupivacaine with epinephrine is primarily used during surgeries requiring local or regional anesthesia, particularly for procedures with extended duration. Key usage domains include:
- Surgical anesthesia
- Obstetric anesthesia
- Dental procedures
Market Size and Segments
The global local anesthetics market reached approximately USD 5.8 billion in 2022, with Bupivacaine representing around 12%. North America accounts for roughly 45% of the market, driven by demand for outpatient and intraoperative anesthesia.
Key Players
Leading manufacturers include:
- Pfizer Inc.
- Hikma Pharmaceuticals
- Teva Pharmaceutical Industries
- Mylan (now part of Viatris)
- AstraZeneca
These companies hold substantial distribution channels and regulatory approvals across major markets.
Regulatory Status
Bupivacaine with epinephrine formulations have received FDA approval, with multiple patent protections expiring in recent years, opening competition to generic versions. Patent expirations have accelerated generic market entry, increasing competition and reducing prices.
Price Trends and Projections
Current Pricing
Wholesale Acquisition Cost (WAC) estimates as of Q1 2023 indicate:
| Manufacturer |
Package Size |
Approximate Price (USD) |
| Branded (Pfizer) |
50 mL vial |
$18 - $22 |
| Generic (Viatris, Hikma, Teva) |
50 mL vial |
$8 - $12 |
The generic versions typically sell at 40-50% discounts relative to branded prices.
Market Drivers Impacting Price
- Patent Expirations: Opened pathways for generics, decreasing prices.
- Regulatory Approvals: Ease of approval for biosimilars and generics expands competition.
- Manufacturing Costs: Slight reductions due to technological advances.
- Reimbursement Policies: Shifts toward value-based models influence pricing strategies.
Future Price Forecasts (Next 5 Years)
Considering market saturation and increased competition, prices are projected to decline further:
| Year |
Estimated Average Price (USD) per 50 mL vial |
| 2023 |
$8.50 - $12.00 |
| 2024 |
$7.50 - $11.00 |
| 2025 |
$6.50 - $10.00 |
| 2026 |
$6.00 - $9.50 |
| 2027 |
$5.50 - $9.00 |
Price compression is expected due to market entry by additional generics and biosimilars, with some stabilization caused by manufacturing quality and supply chain factors.
Market Volume Projections
Global consumption is forecasted to grow at a compound annual growth rate (CAGR) of approximately 3-4%, driven by expanding surgical procedures, aging populations, and increased adoption in emerging markets. Total volume sold could reach 4 million units (50 mL vials) annually by 2027.
Strategic Insights
- Patent expirations accelerate availability of low-cost generics.
- Market entry of biosimilars may influence pricing and supply stability.
- Manufacturers focusing on quality assurance can command premium prices in specific institutional settings.
- Supply chain disruptions could temporarily influence pricing and availability, but overall downward pressure remains.
Key Takeaways
- NDC 70954-0168 (bupivacaine with epinephrine) is part of a broad, mature local anesthetic market.
- Competition from generics has significantly lowered prices, with continuing downward trends.
- Price reductions are forecasted to persist through 2027, with generics dominating market share.
- Market volume is expanding, especially in emerging economies and outpatient care settings.
- Regulatory dynamics, patent cliffs, and manufacturing efficiencies influence future price and market size.
FAQs
1. What factors most influence the price of NDC 70954-0168?
Patent expirations, the number of generic manufacturers, regulatory approvals, and manufacturing costs drive price changes.
2. Will branded versions of this drug maintain higher prices?
Yes, branded products maintain premium pricing due to perceived quality, brand loyalty, and specific formulation advantages.
3. How do regulations affect the market for this drug?
Regulatory approvals facilitate market entry for generics and biosimilars, often leading to price reductions and increased competition.
4. Is there potential for new formulations or delivery methods?
Innovation in delivery (e.g., sustained-release formulations) could alter market dynamics, but current projections assume continuation of existing formulations.
5. What are the key risks to price stability?
Supply chain disruptions, regulatory delays, or patent surges can temporarily affect prices, but long-term trends favor price decreases for generics.
References
- MarketWatch. (2023). Global local anesthetics market size and forecasts. Retrieved from MarketWatch
- IQVIA. (2022). U.S. pharmaceutical market analysis. Retrieved from IQVIA
- U.S. Food and Drug Administration. (2023). Approved drug products. Retrieved from FDA website
- Statista. (2023). Market share of local anesthetics. Retrieved from Statista
- EvaluatePharma. (2023). Pharmaceutical sales forecasts. Retrieved from EvaluatePharma
